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Abstract
Aim: Previous studies have suggested Glypican-3 (GPC3) could be a valuable diagnostic marker for
hepatocellular carcinoma. This study examined the effects of overexpression of GPC3 on Huh-7 hepatoma cells.
Methods: We constructed a recombinant plasmid vector pcDNA3.1 (+)-GPC3 for GPC3 overexpression studies
in Huh-7 cells. RT-PCR and Western blotting were used to confirm GPC3 gene expression. Cell proliferation was
evaluated by 5-ethynyl-2-deoxyuridine (EdU) incorporation assay. Cell cycle progression and apoptosis were
determined by flow cytometry using propidium iodide (PI) and Annexin V-FITC/PI staining, respectively. Cell
migration and invasion were examined by Boyden Transewll and Matrigel assays.
Results: GPC3 overexpression effectively inhibited proliferation, induced cell cycle arrest at S phase and
increased apoptosis in Huh-7 cells. Furthermore, GPC3 overexpression significantly inhibited the migration and
invasion ability of Huh-7 cells.
Conclusion: Our results demonstrate that GPC3 could be a new therapeutic target for hepatocellular carcinoma.
Keywords: Glypican-3; Hepatocellular carcinoma; Apoptosis;
Invasion; Migration; Gene expression
Introduction
Hepatocellular carcinoma is the third leading cause of cancer-
related death in the world [1]. The outcome of patients with
hepatocellular carcinoma is very poor with 5-year survival rate is less
than 10-15% [2,3]. Several clinic pathological features, such as, poorly
differentiated phenotype and portal venous invasion, have suggested
to contribute to the poor prognosis in hepatocellular carcinoma
patients. The underlying molecular mechanisms of the development of
hepatocellular carcinoma remains elusive.
Glypican-3 (GPC3) is a member of the protein glycan family with a
tissue-specific expression [4]. They are released from cell surface and
functional to regulate the cell signaling of migration, proliferation and
cell survival [5,6]. Previous studies have suggested that GPC3 is a
valuable diagnostic biomarker for hepatocellular carcinoma [7,8].
Glypicans regulate several signaling pathways such as Wnts,
hedgehogs, fibroblast growth factors which could exert stimulatory or
inhibitory effects on cells. In cells predominately controlled by
hedgehogs signaling, GPC3 inhibits cell proliferation, whereas in cell
predominately controlled by Wnt signaling pathway, GPC3 stimulates
cell proliferation [9-11]. GPC-3 have shown to be overexpressed in
hepatocellular carcinoma [12]. Silencing GPC3 in hepatocellular
carcinoma cells inhibited cell proliferation and increased cell
apoptosis. Moreover, another study shows that suppression of GPC3
inhibits cell proliferation and cell cycle progression in HepG2 cells but
no significant effect in the Huh-7 cells [9]. However, the potential
effect of overexpression of GPC3 in hepatocellular carcinoma remains
unclear.
In this study, we overexpressed GPC3 in Huh-7 cells by using the
recombinant plasmid pcDNA3.1 (+)-GPC3 to analyze the effects of
GPC3 overexpression on hepatocellular carcinoma.
Materials and Methods
Huh-7 cell culture
Human hepatocellular carcinoma Huh-7cells were purchased from
Japanese Collection of Research Bioresources (JCRB) Cell Bank
(Japan), and were cultured in complete Dulbecco's modified Eagle's
medium (DMEM) (Invitrogen, Carlsbad, CA) supplemented with 10%
fetal bovine serum (FBS), 100 units/ml penicillin, 100 mg/ml
streptomycin, and 2 mM L-glutamine (Invitrogen, Carlsbad, CA).
Construction of plasmid pcDNA3.1 (+)-GPC3
A GPC3-expressing plasmid [pcDNA3.1 (+)-GPC3] was prepared
by using standard recombinant DNA methods [13]. Briefly, full-length
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GPC3 cDNA (GenBank: NM_004484.3) was cloned by reverse





with KpnI and EcoRI restriction sites (underlined bases) were used.
The PCR amplification protocol for GPC3 was: an initial cycle of
denaturation at 98˚C for 2 min, followed by 32 cycles of 98˚C for 15
sec, 68 ˚C for 90 sec, 72˚C for 40 sec and one final cycle at 72˚C for 5
min. The PCR products of GPC3 (1743 bp) were electrophoresed on a
1.2% (W/V) agarose gel, and purified using the DNA purification kit
(Takara, Japan). Then, the purified DNA fragment coding GPC3
sequence was cloned into the plasmid pcDNA3.1 (+) to obtain the
plasmid [pcDNA3.1 (+)-GPC3], which was transformed into DH5α
E.coli. inoculated in LB medium supplemented with 50µg/mL
ampicillin. The proper insert was confirmed by sequencing (Sangon
Biotech, China). The plasmid was extracted using plasmid preparation
kit (Qiagen, Germany) and purified using plasmid purification kit
(Qiagen, Germany) according to the manufacturer’s instruction.
Transfection of pcDNA3.1 (+)-GPC3 into Huh-7 cells
Huh-7 cells were transfected with the plasmid [pcDNA3.1 (+)-
GPC3] by using Lipofectamine 2000 (Invitrogen, Camarillo, USA)
according to the manufacturer’s instruction. GPC3 transfected Huh-7
cells were defined as Huh-7-GPC3 cells. Huh-7 cells transfected with
blank plasmid pcDNA3.1 (+) were defined as mock-transfected cells,
serving as a negative control (NC). The Huh-7 cells without
transfection were defined as (blank) control cells. After 72 hr
transfection, the Huh-7 cells were used for various experiments.
Real time RT-PCR analysis of GPC3 expression
Real-time PCR was carried out on ABI 7900HT real-time PCR
system 7900 (USA) using the PrimeScrip RT-PCR Kit (Takara, Japan)
as previously reported [13]. Briefly, after 48 h of transfection, the total
RNAs were extracted from control, negative control and Huh-7-PGC
cells by using the Trizol reagent (Life Technologies, USA) according to
the manufacturer’s instruction. Then the RNAs were converted into
cDNA using specific primers (forward, 5'-
AGAAACCTTATCCAGCCGAAGAA-3'; reverse, 5'-
TGGGTCCAACTACTAAGCT-3') and reverse transcription kit.
GAPDH was used as an internal control. The relative gene expression
was determined by using the 2-ΔΔCt method. Experiment was
repeated for three times.
Proliferation assay of Huh-7 cells
The Huh-7 cell proliferation was evaluated by using 5-ethynyl-2-
deoxyuridine (EdU) incorporation assay [14]. Briefly, after 72 hr of
transfection, cells were cultured in fresh complete culture medium
(DMEM supplemented with 10% fetal bovine serum (FBS) for 12 hr,
followed by incubation with medium supplemented with 50 mM EdU
(1:1000) (Ribobio, Guangzhou, China) for 2 hr. Then, cells were fixed
for 15 min at room temperature (RT), permeabilized with 0.5% Triton
X-100 in PBS for 20 min, and incubated with apollo® fluorescent dye
(Invitrogen, Carlsbad, CA) for 30 min at RT in the dark. 4', 6-
Diamidino-2- Phenylindole (DAPI) (Invitrogen, Carlsbad, CA) was
used to counterstain the nucleus. Images were taken under a
fluorescent microscope (Olympus, Japan)at three random fields. The
percentage of EdU-positive cells was calculated as: EdU+ cells (%) =
EdU+ cells / DAPI+ cells x 100%. The experiment was performed for
three times.
Cell cycle and apoptosis analyses of Huh-7 cells
Cell cycle progression of Huh-7 cells was determined by flow
cytometry using propidium iodide (PI) [15]. Briefly, after 72hr of
transfection, Huh-7 cells were trypsinized, fixed with cold 75% ethanol
for 1 hr and centrifuged. Then the cell pellet was resuspended and
incubated with PI (50 µg/ml; Beyotime, China) containing RNaseA
(0.1 mg/ml) in PBS for 30 min at RT in the dark. Sample was analyzed
using a FACS can flow cytometer with Cell Quest software (Becton
Dickinson, NJ, USA).
The apoptosis assay of Huh-7 cells was conducted by using Annexin
V-FITC/PI apoptosis detection kit as previously described [16].
Briefly, after 72hr of transfection, Huh-7 cells were washed, incubated
with Annexin V-FITC and PI staining solution (Becton Dickinson,
USA) for 20 min at RT in the dark and then analyzed by flow
cytometer. All experiments were performed for three times.
Migration and invasion assays of Huh-7 cells
The migration and invasion assays of Huh-7 cells was carried out by
using Boyden chamber as previously described [17]. For cell invasion
assay, the porous membrane of the top insert (8.0 µm pore size, BD
Biosciences) was coated with matrigel (40 µl, BD Bioscience, USA) for
2-3 h at 37˚C. After 72 h of transfection, Huh-7 cells (100 µl, 1×105/
well of a 24-well plate) were replaced with fresh serum-free DMEM
and seeded on to the top insert or matrigel-coated top insert. Then,
DMEM supplemented 10% FBS (600 µl) was added into the bottom
well. After 24 h incubation at 37˚C, cells migrated through the porous
membrane to bottom wells were fixed in 75% ethanol for 15 min,
stained with crystal violet solution (Sigma-Aldrich, USA), and cells
invaded through matrigel and membrane to bottom well were directly
counted under an inverted microscope, respectively. All experiments
were repeated for three times.
Western blot analysis of GPC3 expression
After 72 hr transfection, proteins were collected from different
groups by using lysis buffer as previously described [13]. The protein
lysates were then be electrophoresed through SDS-PAGE gel and
transferred onto PVDF membranes. The membranes were blocked
and probed with primary antibodies against GPC3 (Santa cruz, USA)
or GAPDH (Santa cruz, USA) followed by incubation with HRP-
conjugated IgG. Blots were then developed with enhanced chemi-
luminescence developing solutions and quantified under Image J
software.
Statistical Analysis
Data were presented as the mean ± SD (standard deviation).
Comparisons among multiple groups were analyzed by ANOVA using
the SPSS 17.0 software and the comparison between two groups was
analyzed by Student’s t-test. P<0.05 was considered statistically
significant.
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Results
mRNA and protein expression of GPC3 in Huh-7 cells were
increased after plasmid pcDNA3.1 (+)-GPC3 transfection
The real time RT-PCR results showed that the expression level of
GPC3 in the Huh-7 cells transfected with GPC3 was significantly
higher than that in control or mock groups (Figure 1A) (P<0.01,
control or mock Vs. Huh-7-GPC3). There is no significant difference
between control and mock groups (P>0.05, control vs. mock). The
protein expression level of GPC3 was increased in Huh-7-GPC3 cells
as revealed by western blot analysis (Figure 1B and 1C) (P<0.05,
control or mock Vs. Huh-7-GPC3). Similarly, there is no difference of
GPC3 protein expression between control and mock groups (P>0.05,
control Vs. mock).
Figure 1: GPC3 overexpression in Huh-7 cells after GPC3
transfection. A: Relative expression of GPC3 mRNA in Huh-7 cells
transfected with cDNA3.1 (+)-GPC3, blank plasmid (mock), or
control. B: Representative western blot bands of GPC3 protein
expression in in Huh-7 cells transfected with cDNA3.1 (+)-GPC3,
blank plasmid (mock), or control. GAPDH used as a loading
control. C: Summarized data of GPC3 protein expression in three
groups. Data was expressed as mean ± SD, n=3/group, *P< 0.05,
**P< 0.01, versus control or mock.
Overexpression of GPC3 inhibited the proliferation of
Huh-7 cells
The effect of GPC3 overexpression on the proliferation of Huh-7
cells was evaluated by EdU incorporation assay. As shown in Figure 2,
the percentage of EdU-positive cells was significantly decreased in
Huh-7-GPC3 group as compared to that in control and mock groups
(P<0.05, 90.1 ± 5.9%, 91.0 ± 2.5%, and 81.06 ± 3.6% for control, mock
and Huh-7-GPC3, respectively; control or mock Vs. Huh-7-GPC3).
And there was no significant difference of EdU-positive cells between
control and mock groups (P>0.05, control Vs. mock). These results
indicated that overexpression of GPC3 in Huh-7 cells could inhibit cell
proliferation.
Overexpression of GPC3 inhibited Huh-7 cell cycle
progression
As shown in Figure 3, the flow cytometric results showed that there
was a significant increase of S phase Huh-7 cells in GPC3 transfection
group (P<0.05, control or mock Vs. Huh-7-GPC3). In addition, a
concomitant increase of Huh-7 cells in sub G1 phase and reduction of
Huh-7 cells in G2/M phase were observed in the GPC3 transfection
group (P<0.05, control or mock Vs. Huh-7-GPC3 ). And the
proportion of cells at the G1 phase was not significantly changed.
Figure 2: Effect of GPC3 overexpression on EdU incorporation into
Huh-7 cells. A: Representative images of EdU incorporation and
DAPI staining in Huh-7 cells transfected with cDNA3.1 (+)-GPC3,
blank plasmid (mock), or control. Scale bar: 100 μm. B:
Summarized data of Edu expression in the three groups. Data was
expressed as mean ± SD, n=3/group. *P<0.05, versus control or
mock.
Overexpression of GPC3 increased apoptosis of Huh-7 cells
To investigate the potential effect of GPC3 overexpression on
cellular apoptosis, the treated cells were stained with annexin V-
FITC/PI and analyzed by flow cytometry. We found that there were
higher percentages of both early stage apoptotic cells and late stage
apoptosis and necrotic cells in the Huh-7-GPC3 groups when
compared to those in control or mock groups (P<0.05, control or
mock Vs. Huh-7-GPC3; Figure 4A and 4B).
Overexpression of GPC3 decreased the migration and
invasion abilities of Huh-7 cells
Our results showed that Huh-7 cell migration ability was
significantly suppressed in Huh-7-GPC3 cells when compared to that
in control or mock groups (P<0.01, control or mock Vs. Huh-7-GPC3;
Figure 5A). The percentage of cells passed through the membrane of
the inserters to the bottom wells was reduced from 47.3 ± 7.7%
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(control group) or 40.9 ± 10.1% (mock group) to 14.0 ± 5.2% (Huh-7-
GPC3 group). These results supported that GPC3 overexpression
could effectively inhibit cell migration.
Figure 3: Effects of GPC3 overexpression on cell cycle of Huh-7
cells. Summarized data of Huh-7 cells distributed in the subG1, G1,
G2/M and S phase in control, mock and GPC3 overexpression
groups. Data was expressed as mean ± SD, n=3/group. *P<0.05,
versus control or mock.
Figure 4: Effects of GPC3 overexpression on apoptosis of Huh-7
cells. A: Representative flow cytometric plots showing the
distribution of Huh-7 cells in the three group. Cells in the lower
right quadrants were defined early apoptotic cells. Cells in the
upright quadrants were defined as late apoptosis cells. B.
Summarized data of Huh- 7 cell apoptosis in the three groups. Data
was expressed as mean ± SD, n=3/group. *P<0.05, versus control or
mock.
The results of invasion assay showed that GPC3 overexpression
significantly lowered the invasion activity of Huh-7 cells as compared
to those in control or mock groups (P<0.05, control or mock Vs.
Huh-7-GPC3; Figure 5B). The percentage of cells invaded through the
matrigel and membrane to the bottom wells was apparently decreased
from 7.9 ± 1.5% (control group) or 10.6 ± 4.2% (mock group) to 4.9 ±
1.2% (Huh-7-GPC3 group). These results showed that GPC3
overexpression could effectively suppress GPC3 cell invasion.
Discussion
In the present study, we found that overexpression of GPC3 in
Huh-7 cells can inhibit cell proliferation, induce apoptosis, arrest cell
cycle progression at the S phase, and suppress Huh-7 cell migration
and invasion.
Figure 5: Effects of GPC3 overexpression on the migration and
invasion abilities of Huh-7 cells. A: Summarized data of Huh-7 cell
migrated through the polycarbonate membrane with 8.0 μM pore
size to the bottom wells in the control, mock and Huh-7-GPC3
groups. B: Summarized data of Huh-7 cell invaded through the
matrigel-coated membrane to the bottom wells in the control,
mock and Huh-7-GPC3 groups. Data was expressed as mean ± SD,
n=3/group. *P< 0.05, **P< 0.01, versus control or mock.
GPC3 is a member of the glypican family that plays an important
role in modulating cell growth, migration, invasion and cell cycle
progression [18,19]. The protein expression of GPC3 is up-regulated
in hepatocellular carcinoma [12]. Interestingly, we found that GPC3
overexpression could effectively inhibiting cell proliferation as
revealed by using EdU staining in the Huh-7 cells. We speculate that
the inhibition of cell proliferation resulted from cell cycle arrest,
because cell cycle checkpoints are critical intersections for cell growth.
In order to validate our hypothesis regarding to the suppression of cell
proliferation is associated with cell cycle arrest, we determined Huh-7
cell cycle progression by flow cytometry. Our results revealed that
overexpression of GPC3 arrested Huh-7 cells at S phase, decreased the
percentage of Huh-7 cells at G2/M phase, and concurrently increased
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cell apoptosis and necrosis at sub G1 phase. Our cell proliferation data
are in line with the cell cycle results. For proliferation assay, the EdU
positive cells were measured after an additional 12 hrs culture
following GPC3 overexpression. Whereas, for cell cycle assay, PI
staining was performed immediately following GPC3 overexpression.
The EdU experiment revealed a decrease in the percentage of S phase
cells, suggesting the inhibitive effect of GPC3 on cell proliferation. For
the PI experiment, we observed an increase in the percentage of S
phase cells. This could be interpreted by S phase cell accumulation
because we found that there was a decrease in percentage of G2/M
phase cells, indicating that GPC3 prevents cells enter into G2/M phase.
These data generated from different experiment protocols together
suggest that the growth-inhibitory effects of GPC3 overexpression
could result from changes in the cell cycle.
Several previous studies have suggested the involvement of GPC3 in
hepatocellular carcinoma [12,20,21]. Of note, silencing GPC3 in
hepatocellular carcinoma cells has been shown to inhibit cell
proliferation and increase cell apoptosis [21]. Moreover, a study has
shown that suppression of GPC3 inhibits cell proliferation and cell
cycle progression in HepG2 cells but no significant effect in the Huh-7
cells [9]. Such a discrepancy could exist because of different cell lines
as well as experimental conditions applied for the studies.
Nevertheless, the more underlying mechanisms require further
investigation.
Apoptosis induction is considered as a very useful approach for
cancer therapy. Many studies have indicated that GPC3 plays an
important role in regulating cell survival [18,19]. A previous report
showed that murine mammary tumor LM3 cells overexpressing GPC3
were much more sensitive to apoptosis induction [22]. Consistently,
we observed that Huh-7 cells transfected with GPC3 plasmid had a
increased percentage of apoptotic rate in this study.
It is well-known that cell migration and invasion play a crucial role
in cancer [23]. And proteolytical disruption of basement membrane is
a key step involved in the migration and invasion processes. In the
present study, we examined the migration and invasion abilities of the
Huh-7 cells trasnfected with GPC3 plasmid. Our results showed that
overexpression of GPC3 in Huh-7 cells significantly inhibited cell
migration and invasion. Further studies will be performed to clarify
the mechanisms underlying the biologic effects of GPC3 on Huh-7
cells.
In conclusion, our results demonstrate that the overexpression of
GPC3 in Huh-7 cells inhibits cell proliferation, induces apoptosis
associated with arresting cell cycle progression at the S phase, and
suppresses cell migration and invasion. These data indicate the
diagnostic and therapeutic potential of GPC3 in hepatocellular
carcinoma patients.
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